These compounds include inhibitors targeting the BCR/PI3K/AKT/mTOR pathway, agents that suppress MYC transcription or disrupt MYC function, as well as molecules that interfere with tumour cell metabolism or alter cell cycle and apoptosis regulation through inhibition of CDK4/6 or modulation of anti-apoptotic proteins such as MCL-1 [111,113]. Here, MYC is linked to neoplasm.